Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-003 intrathecal study in early-manifest Huntington's disease
NL-OMON53854Phase 2Not yet recruiting
- Sponsor
- Wave Life Sciences
- Start
- Jul 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing WVE-003 with Placebo (2 arms). Planned start Jul 2023; status: not yet recruiting.
02
Drugs
WVE-003
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON53854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53854.